ADMA

ADMA Biologics Inc

ADMA, USA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

https://www.admabiologics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ADMA
stock
ADMA

High Growth US Tech Stocks To Watch In January 2026 Yahoo Finance

Read more →
ADMA
stock
ADMA

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know Yahoo Finance

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$25.6667

Analyst Picks

Strong Buy

2

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

20.45

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

9.85

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

8.45 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Medium

6.41 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-0.80 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.32

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 84.45% of the total shares of ADMA Biologics Inc

1.

BlackRock Inc

(15.2844%)

since

2025/06/30

2.

Vanguard Group Inc

(8.9526%)

since

2025/06/30

3.

iShares Core S&P Small-Cap ETF

(5.9492%)

since

2025/08/31

4.

Amvescap Plc.

(5.3715%)

since

2025/06/30

5.

State Street Corp

(5.0616%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(3.0049%)

since

2025/07/31

7.

Geode Capital Management, LLC

(2.4779%)

since

2025/06/30

8.

iShares Russell 2000 ETF

(2.3378%)

since

2025/08/31

9.

Nuveen, LLC

(2.3312%)

since

2025/06/30

10.

Dimensional Fund Advisors, Inc.

(1.996%)

since

2025/06/30

11.

American Century Companies Inc

(1.9323%)

since

2025/06/30

12.

Allspring Global Investments Holdings, LLC

(1.3914%)

since

2025/06/30

13.

Thrivent Financial For Lutherans

(1.3894%)

since

2025/06/30

14.

SPDR® S&P Biotech ETF

(1.3602%)

since

2025/08/31

15.

FMR Inc

(1.3463%)

since

2025/06/30

16.

Renaissance Technologies Corp

(1.3184%)

since

2025/06/30

17.

Oberweis Asset Management Inc

(1.3141%)

since

2025/06/30

18.

Perpetual Ltd

(1.2129%)

since

2025/06/30

19.

Vanguard Small Cap Index

(1.1525%)

since

2025/07/31

20.

Franklin Resources Inc

(1.1394%)

since

2025/06/30

21.

American Century Small Cap Growth Inv

(1.098%)

since

2025/06/30

22.

American Century U.S. Small Cap Growth

(1.098%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0753%)

since

2025/07/31

24.

Charles Schwab Investment Management Inc

(1.0485%)

since

2025/06/30

25.

Driehaus Capital Management LLC

(1.038%)

since

2025/06/30

26.

Northern Trust Corp

(1.0239%)

since

2025/06/30

27.

UBS Group AG

(1.0148%)

since

2025/06/30

28.

Ranger Investment Management LP

(1.0017%)

since

2025/06/30

29.

Fidelity Small Cap Index

(0.9746%)

since

2025/06/30

31.

CREF Stock R3

(0.8632%)

since

2025/07/31

32.

iShares S&P Small-Cap 600 Growth ETF

(0.8609%)

since

2025/08/31

33.

iShares Russell 2000 Growth ETF

(0.8542%)

since

2025/08/31

34.

Invesco Main Street Small Cap R6

(0.8064%)

since

2025/07/31

35.

Thrivent Small Cap Stock A

(0.797%)

since

2025/06/30

36.

Ranger Small Cap

(0.7907%)

since

2025/06/30

37.

Putnam US Small Cap Growth Managed Acct

(0.7313%)

since

2025/06/30

38.

Putnam US Small Cap Growth Equity

(0.7313%)

since

2025/06/30

39.

Putnam Small Cap Growth A

(0.7313%)

since

2025/07/31

40.

Invesco Small Cap Core

(0.6996%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.1867

Latest Release

Date

2025-09-30

EPS Actual

0.15

EPS Estimate

0.15

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(7.5)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
High Quality(6.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.